Positive results for drug combo in I-SPY 2 trial.
In results from one part of the I-SPY 2 trial announced at the 2013 San Antonio Breast Cancer Symposium, neoadjuvant veliparib plus carboplatin improved outcomes for women with triple-negative breast cancer.